PRFX - PainReform Ltd.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Tel Aviv,
Israel
Type: Equity
PRFX price evolution
PRFX
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $2.99 | $5.25 | $9.8 | $10.74 |
| Long term investments | ||||
| Property, plant & equipment | $0.12 | $0.12 | $0.13 | $0.15 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $3.11 | $5.37 | $9.93 | $10.89 |
| Current liabilities | ||||
| Accounts payable | $0.12 | $0.21 | $0.22 | $0.21 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $4.89 | $3.25 | $2.41 | $1.09 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $5.15 | $3.52 | $2.69 | $2.25 |
| Shareholders' equity | ||||
| Retained earnings | -$54.68 | -$47.37 | -$41.86 | -$36.97 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $15.69 | |||
| Short term investments | ||||
| Net receivables | $0.04 | $0.06 | $0.22 | $0.05 |
| Inventory | ||||
| Total current assets | $9.8 | $12.28 | $19.02 | $17.79 |
| Long term investments | ||||
| Property, plant & equipment | $0.13 | $0.04 | $0.05 | $0.01 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.01 | |||
| Total investments | ||||
| Total assets | $9.93 | $12.33 | $19.07 | $17.8 |
| Current liabilities | ||||
| Accounts payable | $0.22 | $0.21 | $0.14 | $0.96 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2.41 | $1.06 | $0.76 | $0.96 |
| Long term debt | ||||
| Total noncurrent liabilities | $0.22 | |||
| Total debt | ||||
| Total liabilities | $2.69 | $1.31 | $0.99 | $1.18 |
| Shareholders' equity | ||||
| Retained earnings | -$41.86 | -$32.52 | -$23.73 | -$16.48 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 | 29 Oct 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $1.67 | $1.74 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.01 | |||
| Interest expense | -$0.02 | $0.02 | ||
| Net income | ||||
| Net income | -$1.69 | -$1.73 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $7.21 | $1.67 | $0.69 | $0.5 |
| Operating income | -$1.67 | -$0.69 | ||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.01 | $0.22 | ||
| Interest expense | -$0.02 | $2.16 | $0.59 | -$0.33 |
| Net income | ||||
| Net income | -$7.25 | -$4.05 | -$1.28 | -$0.83 |
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 | 29 Oct 2021 |
|---|---|---|---|---|
| Net income | -$5.51 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$4.78 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0 | -$0.05 | -$0.02 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $7.48 | $7.48 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.7 | -$1.13 | $0.88 | $2.68 |
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Net income | -$4.05 | -$1.28 | ||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$2.56 | -$0.61 | ||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.05 | -$0.01 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $7.48 | $17.31 | $1.51 | $0.49 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $0.88 | $14.74 | $0.9 | -$0.15 |
News
Fundamentals
| Market cap | $11.10M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 3.47M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.61 |
| Quick ratio | N/A |